Fatty Liver

Fatty liver, also known as fatty liver disease (FLD), is a reversible condition where large vacuoles of triglyceride fat accumulate in liver cells via the process of steatosis (i.e. abnormal retention of lipids within a cell).

What is Fatty Liver?

Fatty liver is a very common disorder and up to 20 percent of adults and approximately 5 percent of children are affected.

Fatty Liver Pathology

Fatty Liver Diagnosis

Acute Fatty Liver of Pregnancy Treatment

Liver fat may disrupt post-meal glucagon control in early type 2 diabetes

Researchers found that MASLD, rather than type 2 diabetes alone, was linked to higher fasting glucagon levels in adults with newly diagnosed diabetes and matched controls. In people with early type 2 diabetes, higher liver fat was specifically associated with exaggerated early post-meal glucagon responses, independent of insulin sensitivity, visceral fat, amino acids, or NEFAs.

10 May 2026

Asthma medication formoterol shows promise for treating fatty liver disease

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds of millions worldwide.

8 May 2026

Advanced heart, kidney and metabolic disease linked to higher cancer risk

People with advanced heart, kidney and metabolic disease may face a higher risk of developing cancer, according to new research published today in the American Heart Association's peer-reviewed scientific journal Circulation: Population Health and Outcomes.

27 Apr 2026

Prediabetes leaves lasting fat tissue changes after bariatric surgery

Prediabetes may leave a lasting molecular "footprint" on adipose (fat) tissue which appears to make maintaining weight loss after bariatric surgery more difficult, according to new research being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

22 Apr 2026

Immune cell interactions drive liver inflammation and fibrosis

When the liver is injured - for example, due to bile accumulation - immune cells become activated. In mouse experiments, the Würzburg team observed that certain immune cells undergo functional changes in response to liver damage, adopting a highly pro-inflammatory state.

21 Apr 2026

Eating oranges daily may shift lipid patterns in fatty liver disease

A 4-week trial on 'Navelina' oranges shows potential effects on lipid metabolism in fatty liver disease, revealing intriguing but non-significant patterns.

20 Apr 2026

Researchers discover a molecular signature to flag dysfunctional aging cells

UCLA researchers have identified a rogue population of immune cells that quietly accumulates in aging tissues and in the livers of people with fatty liver disease. Clearing these cells, they found, dramatically reduced inflammation and reversed liver damage in mice - even while the animals remained on an unhealthy diet.

16 Apr 2026

Gut-liver changes drive foodborne infection severity in fatty liver disease

A research team led by the University of California, Irvine's Joe C. Wen School of Population & Public Health has uncovered a critical biological link explaining why individuals with metabolic dysfunction–associated steatotic liver disease (MASLD), or fatty liver disease, face significantly worse outcomes from certain foodborne infections.

15 Apr 2026

Semaglutide improves liver function independently of weight loss

Researchers at Toronto's Sinai Health have found that semaglutide – the active ingredient in popular weight loss drugs that mimic the gut hormone GLP-1 – acts directly on a subset of liver cells to improve organ function and does so independently of weight loss.

15 Apr 2026

Waist-to-height ratio outperforms BMI in predicting hypertension risk

New waist-to-height cut-offs to assess fat mass and obesity predicted the risk of hypertension better than body mass index, according to a new study from the University of Eastern Finland and the Robert Wood Johnson Medical School at Rutgers University in the US.

14 Apr 2026

Weight gain timing affects long-term health outcomes

When in life we gain weight can have a significant impact on our health many years later. In a study involving over 600,000 people, researchers at Lund University in Sweden have investigated how changes in weight between the ages of 17 and 60 are linked to the risk of dying from various diseases

11 Apr 2026

Higher sugar intake raises gallstone risk in adults, study finds

A cross-sectional NHANES study of 8,975 U.S. adults found that higher total dietary sugar intake was associated with higher odds of gallstones, with each 100 g/day increase linked to a 41% rise after full adjustment. The findings suggest sugar intake may be a modifiable gallstone risk factor, but the study relied on self-reported gallstones and cannot establish causation.

29 Mar 2026

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Expert consensus validates UDFF for noninvasive fatty liver assessment

As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent chronic liver conditions worldwide. Its progressive forms, including metabolic dysfunction‐associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma, now represent a major public health challenge.

17 Mar 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026

Low testosterone and high fructose intake can worsen fatty liver disease

Low testosterone in itself can cause a variety of health problems, but the addition of a poor diet can exacerbate certain conditions. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one example that approximately 40% of adult men worldwide currently suffer from and has become a global problem.

11 Mar 2026

EVA1A regulates fatty acid transporter CD36 in fatty liver disease

Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, obesity, and diabetes prevalence, making it one of the most common chronic liver diseases worldwide.

9 Mar 2026

No evidence probiotic skincare can improve mood

Current findings reveal no support for emotional benefits from probiotic cosmetics, highlighting the need for further investigation into neurocosmetics.

5 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

New review explains how circular RNAs could unlock fat browning therapies

A Cell Death & Disease review synthesizes preclinical evidence that circular RNAs regulate adipose browning and metabolic pathways through microRNA interactions, protein binding, and organelle-linked stress mechanisms. It highlights their biomarker and therapeutic potential in obesity and type 2 diabetes while underscoring key translational challenges, including delivery specificity and human validation.

26 Feb 2026